Neurocrine

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Neurocrine and other ETFs, options, and stocks.

About NBIX

Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company, which engages in the research and development, commercialization, and sale of pharmaceuticals for the treatment of neurological, neuroendocrine, and neuropsychiatric disorders. Its portfolio of products includes treatments for tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia (CAH), and endometriosis and uterine fibroids.

CEO

Kyle W. Gano

CEOKyle W. Gano

Employees

2,000

Employees2,000

Headquarters

San Diego, California

HeadquartersSan Diego, California

Founded

1992

Founded1992

Employees

2,000

Employees2,000

NBIX Key Statistics

Market cap

13.84B

Market cap13.84B

Price-Earnings ratio

20.71

Price-Earnings ratio20.71

Dividend yield

—

Dividend yield—

Average volume

1.48M

Average volume1.48M

High today

$140.79

High today$140.79

Low today

$134.89

Low today$134.89

Open price

$139.60

Open price$139.60

Volume

1.56M

Volume1.56M

52 Week high

$186.12

52 Week high$186.12

52 Week low

$122.14

52 Week low$122.14

Stock Snapshot

With a market cap of 13.84B, Neurocrine(NBIX) trades at $135.13. The stock has a price-to-earnings ratio of 20.71.

On 2026-10-13, Neurocrine(NBIX) stock moved within a range of $134.89 to $140.79. With shares now at $135.13, the stock is trading +0.2% above its intraday low and -4.0% below the session's peak.

Trading volume for Neurocrine(NBIX) stock has reached 1.56M, versus its average volume of 1.48M.

Over the past 52 weeks, Neurocrine(NBIX) stock has traded between a high of $186.12 and a low of $122.14.

NBIX News

Barron's 3h

This Biopharma Stock Offers Compelling Upside After a Pullback - Barron's

...

Zacks 13h

NBIX vs. SDZNY: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Drugs sector have probably already heard of Neurocrine Biosciences (NBIX Quick QuoteNBIX - Free Report)...

TipRanks 2d

Neurocrine price target lowered to $150 from $164 at BMO Capital

BMO Capital lowered the firm’s price target on Neurocrine (NBIX) to $150 from $164 and keeps a Market Perform rating on the shares as part of a broader research...

Analyst ratings

87%

of 31 ratings

Buy

87.1%

Hold

12.9%

Sell

More NBIX News

Simply Wall St 6d

How Investors Are Reacting To Neurocrine Biosciences New VYKAT XR Data

Neurocrine Biosciences reported that multiple new clinical and real world data sets on VYKAT XR in Prader Willi syndrome will be presented at the FPWR 2026 conf...

Simply Wall St 7d

Neurocrine Biosciences After New VYKAT XR Data Why The Undervalued Narrative Persists

Neurocrine Biosciences (NBIX) is back in focus after announcing a slate of new VYKAT XR and Prader Willi syndrome data that will be presented at the FPWR 2026 c...

People also own

Based on the portfolios of people who own NBIX. This list is generated using Robinhood data, and it’s not a recommendation.

iShares MSCI Emerging Mar…

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.